Novel Genomic Technology Development Direct to Phase II SBIR (R44)

The summary for the Novel Genomic Technology Development Direct to Phase II SBIR (R44) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Novel Genomic Technology Development Direct to Phase II SBIR (R44): This Funding Opportunity Announcement (FOA) encourages Direct to Phase II SBIR grant applications from small businesses to catalyze major advances in genomics through technology development (beyond developing nucleic acid sequencing technologies). The goal is to provide a mechanism for support of very novel and high impact work from across this gamut of genomics technology development. This initiative seeks to support technologies that will have a major impact in the next three to five years.
Federal Grant Title: Novel Genomic Technology Development Direct to Phase II SBIR (R44)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-16-017
Type of Funding: Grant
CFDA Numbers: 93.172
CFDA Descriptions: Human Genome Research
Current Application Deadline: Jan 11, 2017
Original Application Deadline: Jan 11, 2017
Posted Date: Oct 27, 2015
Creation Date: Oct 27, 2015
Archive Date: Feb 11, 2017
Total Program Funding:
Maximum Federal Grant Award: none
Minimum Federal Grant Award: none
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Small businesses
Additional Information on Eligibility
Other Eligible Applicants include the following:
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PAR-16-017.html
Grant Announcement Contact
NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants
Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed)
Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed)
NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed)
Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Op...
Research on the Impact of and Methods for Implementing Regional Genomic Medicine eConsult ...
Near-Term Technology Development for Genome Sequencing - SBIR (R43/R44)
Near-Term Technology Development for Genome Sequencing - STTR (R41/R42)
Revolutionary Genome Sequencing Technologies - The $1000 Genome - SBIR (R43/R44)
More Grants from the National Institutes of Health
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com